

Aiforia Technologies Plc – Managers’ Transactions

Aiforia Technologies Plc, Company Release, Managers’ Transactions, December 19, 2023 09:00 a.m. EET

Person subject to the notification requirement

Name: Westerling-Bui, Thomas Orjan

Position: Other senior manager

Issuer: Aiforia Technologies Plc

LEI: 743700TJRVBX7420Y723

Notification type: INITIAL NOTIFICATION

Reference number: 743700TJRVBX7420Y723_20231215132059_18

Transaction date: 2023-12-15

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Instrument name: Aiforia Technologies 2022 II 7 options

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 50000 Unit price: 0.00 EUR

Aggregated transactions

(1): Volume: 50000 Volume weighted average price: 0.00 EUR

Further inquiries

Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc

tel. +358405009878

<https://investors.aiforia.com/>

Certified Adviser

UB Securities Ltd

ubs@unitedbankers.fi

About Aiforia

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.

Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.

Find out more at www.aiforia.com